Skip to content

Goals for Epilepsy Clinic Visits Trial

Drug-Resistant Epilepsy (DRE) Goals for Epilepsy Clinical Visits mHealth Epilepsy Visit Planner Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05928598
Enrollment
152
Registered
2023-07-03
Start date
2023-09-27
Completion date
2027-01-01
Last updated
2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Resistant Epilepsy

Keywords

Survey, Quality of life, Communication tool, Patient-provider communication

Brief summary

The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the Epilepsy Visit Planner) have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group. * Patients that receive the Epilepsy Visit Planner will have improved quality of life scores. * The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study. Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.

Interventions

BEHAVIORALSurvey questionnaires

Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

BEHAVIORALEpilepsy Visit Planner

Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner. Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

BEHAVIORALQuestionnaires for Providers

Providers will be asked to complete a survey after the clinic visit for the intervention group.

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
University of Michigan
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Enrollment for the trial will include 76 participants for the standard care arm and will include 76 participants for the intervention arm (who will receive the Epilepsy Visit Planner). The study team will enroll for the standard arm and then for the intervention arm for an approximate total of 152 participants. Additionally, approximately 10 providers will be enrolled.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

- Patient Participants: * Adults with drug-resistant epilepsy * Participants receiving care through the Epilepsy clinics at the University of Michigan

Exclusion criteria

- Patient Participants: * \<18 years old * Non-English speaking * Do not clearly have drug-resistant epilepsy * Moderate-to-severe cognitive impairment that precludes study questionnaire completion Inclusion Criteria - Provider Participants: -University of Michigan epilepsy providers

Design outcomes

Primary

MeasureTime frameDescription
Perceived Efficacy in Patient-Physician Interactions Questionnaire (PEPPI), difference in mean score between trial armsBaselineThis is a 10-item measure with Likert scale (range 1-5 for each response) with a score range of 10-50 (higher score indicating higher perceived efficacy in communicating with providers).

Secondary

MeasureTime frameDescription
Perceived Involvement in Care (PICS), difference in mean score between trial armsBaselineThis is a 13-item measure with binary agree/disagree responses (0 points for disagree and 1 point for agree) and higher scores reflecting a greater degree of perceived patient activity and involvement.
Quality of Life in Epilepsy (QOLIE-10) inventory, difference in mean score between trial arms3 months after baseline visitThis is a 10-item measure with Likert scale (range 1-5 for each response) with a score range of 10-50 (lower score indicates better health outcome).
Feasibility, assessed in intervention armBaseline - intervention arm onlyThree questions will be asked regarding if the Planner was completed, if the Planner was shared during the visit, and how the Planner impacted visit length. Both patient participants and provider participants will complete these questions.
Acceptability of Intervention Measure, assessed in intervention armBaseline - intervention arm onlyThere are 4 questions that will be completed by the patient participants and provider participants that evaluate the acceptability of the intervention. The question responses have a Likert scale from 1(completely disagree) to 5 (completely agree). There is a range from 5-25 with a higher score indicating a higher acceptability of the intervention tool.

Countries

United States

Contacts

Primary ContactQueen Bolden
qmbolden@umich.edu734-615-5495

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026